Evoke Pharma Inc: Nasdaq/NYSE listing notice — Evoke Pharma faces Nasdaq delisting; hearing set for March 7, 2024

Evoke Pharma Inc

Received Nasdaq notice on Nov 21 for non-compliance with Minimum Stockholders' Equity Requirement of $2.5M.
Hearing before Nasdaq Hearings Panel scheduled for March 7, 2024; delisting action stayed pending outcome.
Company exploring options including raising capital, but no assurance of regaining compliance.
Non-compliance risk could lead to transfer to OTC markets if delisted.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Evoke Pharma Inc received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: stockholders equity
Rules: 5550(b)(1)

Exact text from the filing

November 21, 2023, Evoke Pharma, Inc. (the “Company”) received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) that, due to the Company’s non-compliance with Nasdaq Listing Rule 5550(b)(1) (the “Minimum Stockholders’ Equity Requirement”),which requires listed companies to maintain stockholders’ equity of at least $2.5 million, the Company was subject to delisting unless it timely requested a hearing before the Nasdaq Hearings Panel (the “Hearings Panel”). On November 27, 2023, Nasdaq notified the Company that the hearing was scheduled for M

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0000950170-23-066558

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.